|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2011-11-26 07:32 编辑
回复 ainile 的帖子
1. Suppress persistently replication in Chronic Hepatitis with significant disease and in all cirrhotic patients. 压制坚持复制在所有重大疾病的慢性肝炎和肝硬化患者。
2. whenever possible aim at ‘pathogenetically relevant” endpoints…只要有可能，目的是在“pathogenetically有关”终结点..
3. avoid undue reactivations and sub-optimal antiviral regiments避免不必要的重新激活和次优的抗病毒药物
4. remember that the cccDNA is the central molecule and template of HBV replication. A better understanding of the mechanisms that regulate cccDNA function and stability need to be further investigated (bridge with innate/adaptaive immune response, signals, pathways, cytokines…identify new therapeutic targets)…Combination therapies.
记得cccDNA的是中央分子和HBV复制模板。一个更好地了解cccDNA的功能和稳定的机制，规范还需要进一步调查（先天/适应性免疫反应的桥梁，信号，通路，细胞因子......发现新的治疗靶点）...联合疗法。
5. cccDNA clearance is most likely not achievable within the near future…. Possibility we do not need to clear all cccDNA for a (clinical) cure of HBV patients (“epigenetic” and immune control)cccDNA的清除在不久的将来可能无法实现......。我们并不需要清除所有的cccDNA,
乙肝患者治愈（临床）（可“后生”和免疫的控制）
6. Need for noninvasive surrogate parameters for cccDNA load/function in patients with hepatitis B (HBsAg quantitation ??)需要乙肝患者非侵入性的替代cccDNA的负载/功能参数
（乙肝表面抗原定量？？） |
|
发表于 2011-11-24 11:11
